Plain-English translation of NCT05936970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →PRIMA-102 is a study that aims to predict how well a new arthritis medication will work for you by analyzing a simple blood test. Researchers believe they can look at certain markers in your blood to predict whether your new treatment will be effective before you've been on it for long. This research could help doctors choose the best medication for each patient from the start.
Many people with rheumatoid arthritis don't respond well to their first or second medication, which means months of waiting and suffering before finding a treatment that works. This study hopes to develop a blood test that can predict treatment success upfront, so doctors can choose the right medication faster and patients can avoid prolonged trial-and-error.
You will have two main visits: a screening visit at the start and a follow-up visit 12 weeks after you begin your new medication. At both visits, your doctor will draw a blood sample and assess how your arthritis is responding. Between visits, you'll take your new medication as prescribed by your regular doctor—this study doesn't change your normal treatment plan, it just tracks how well it's working.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States